Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
One year ago, World Health Organization Director-General Tedros Adhanom declared the COVID-19 outbreak to be a pandemic. At the time of the announcement, the WHO noted that there were 118,000 cases reported globally, but in its most recent situation report, the WHO indicated that as of March 7, 2021 there have been 116,166,652 cases globally.
The response to the COVID-19 pandemic by the global biopharmaceutical industry over the past fourteen months has been unprecedented. From December 30, 2019, when SARS coronavirus was first detected in a patient sample, and January 10, 2020, when the complete genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was released, multiple treatments and vaccines have been developed and approved for use in combating COVID-19. And the rapid development of these treatments and vaccines has, as the Pharmaceutical Research and Manufacturers of America (PhRMA) recently put i
Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women s Cancer
Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session
Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., March 10, 2021 /PRNewswire/ Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women s Cancer, March 19-25 (#SGOMtg). These investigational data include the first presentation of efficacy and safety results from the KEYNOTE-775/Study 309 study, a multi-center, randomized, open-label, Phase 3 trial (NCT03517449) evaluating KEYTRUDA in combination with LENVIMA in certa
Wednesday, March 10
Lecture Time: 12:45 - 13:00
Live Discussion: 17:00 - 17:30
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE, Phase 3 Studies of Aducanumab in Patients with Early Alzheimer s Disease
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 12:45 - 13:00
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Efficacy in Early Alzheimer s Disease.
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 13:00 - 13:15
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Safety in Early Alzheimer s Disease.
This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
AI reveals current drugs that may help combat Alzheimer’s
New treatments for Alzheimer’s disease are desperately needed, but numerous clinical trials of investigational drugs have failed to generate promising options. Now a team at Harvard-affiliated Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) has developed an artificial intelligence-based method to screen currently available medications as possible treatments for Alzheimer’s disease. The method could represent a rapid and inexpensive way to repurpose existing therapies into new treatments for this progressive, debilitating neurodegenerative condition. Importantly, it could also help reveal new, unexplored targets for therapy by pointing to mechanisms of drug action.